Increase titers for improved manufacturability ofโ difficult-to-express Fabโ
While discovering a novel therapeutic protein can be ground-breaking, manufacturing the biologic drug is often a big barrier to bringing it to market especially for the next-gen modalities which donโt exist in nature. Producing novel proteins at high titers with high quality is a crucial challenge that has long been the expertise of Absci.
Here, we provide a practical example of how we employed AI technology to identify novel chaperones, including one that helped double the production titer of a hard-to-produce protein. Interestingly, this protein sequence wasnโt characterized as a chaperone in the public databases, and had less than 24% sequence homology to any of the canonical chaperones. The Denoviumโข AI engine described here aims to predict functionality of any protein sequence (instead of just structure) and this example describes a powerful application of such a technology.
How can AI address manufacturability?
- Discovering a drug is only the first step – manufacturing the drug with high titer and quality is a crucial challenge
- Absci delivers high titer cell lines with our folding & expression solutions library, which includes chaperones
- For a difficult-to-express Fab, known chaperones identified using traditional approaches for protein discovery weren’t sufficient enough to drive the desired titer increases
- How could we solve the problem by characterizing the whole CHAPERONE UNIVERSE?